uric acid has been researched along with Thromboembolism, Venous in 5 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Whether gout, the most common rheumatologic inflammatory arthritis, or its cause, elevated serum uric acid (SUA), is associated with VTE incidence is unknown." | 7.83 | Serum uric acid, gout, and venous thromboembolism: The atherosclerosis risk in communities study. ( Folsom, AR; Kubota, Y; McAdams-DeMarco, M, 2016) |
| "Fifty episodes of VTE recurrence occurred during the follow-up and Kaplan-Meier survival analysis showed that subjects in the lower tertile of SUA distribution had significantly lower risk of future VTE recurrence (P = ." | 5.62 | Serum uric acid levels and the risk of recurrent venous thromboembolism. ( Agostini, C; Caberlotto, L; Callegari, E; Cinetto, F; De Lucchi, L; Faggin, E; Martini, E; Nardin, C; Pagliara, V; Pauletto, P; Plebani, M; Raggi, D; Rattazzi, M; Sponchiado, A; Villalta, S, 2021) |
| " Whether gout, the most common rheumatologic inflammatory arthritis, or its cause, elevated serum uric acid (SUA), is associated with VTE incidence is unknown." | 3.83 | Serum uric acid, gout, and venous thromboembolism: The atherosclerosis risk in communities study. ( Folsom, AR; Kubota, Y; McAdams-DeMarco, M, 2016) |
| "Fifty episodes of VTE recurrence occurred during the follow-up and Kaplan-Meier survival analysis showed that subjects in the lower tertile of SUA distribution had significantly lower risk of future VTE recurrence (P = ." | 1.62 | Serum uric acid levels and the risk of recurrent venous thromboembolism. ( Agostini, C; Caberlotto, L; Callegari, E; Cinetto, F; De Lucchi, L; Faggin, E; Martini, E; Nardin, C; Pagliara, V; Pauletto, P; Plebani, M; Raggi, D; Rattazzi, M; Sponchiado, A; Villalta, S, 2021) |
| "Gout was associated with higher risk of venous thromboembolism compared with controls (absolute rate 37." | 1.51 | Venous thromboembolism in patients with gout and the impact of hospital admission, disease duration and urate-lowering therapy. ( Clarson, L; Mallen, C; Muller, S; Roddy, E; Sultan, AA; Whittle, R, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, G | 1 |
| Zhuo, N | 1 |
| Liu, Z | 1 |
| Ji, L | 1 |
| Shu, P | 1 |
| De Lucchi, L | 1 |
| Nardin, C | 1 |
| Sponchiado, A | 1 |
| Raggi, D | 1 |
| Faggin, E | 1 |
| Martini, E | 1 |
| Pagliara, V | 1 |
| Callegari, E | 1 |
| Caberlotto, L | 1 |
| Plebani, M | 1 |
| Pauletto, P | 1 |
| Cinetto, F | 1 |
| Agostini, C | 1 |
| Villalta, S | 1 |
| Rattazzi, M | 1 |
| Sultan, AA | 1 |
| Muller, S | 1 |
| Whittle, R | 1 |
| Roddy, E | 1 |
| Mallen, C | 1 |
| Clarson, L | 1 |
| Kubota, Y | 1 |
| McAdams-DeMarco, M | 1 |
| Folsom, AR | 1 |
5 other studies available for uric acid and Thromboembolism, Venous
| Article | Year |
|---|---|
The risk of venous thromboembolism increases within one month of gout flare: comment on the article by Cipolletta et al.
Topics: Gout; Gout Suppressants; Humans; Symptom Flare Up; Uric Acid; Venous Thromboembolism | 2023 |
A Mendelian randomization study of serum uric acid with the risk of venous thromboembolism.
Topics: Genome-Wide Association Study; Humans; Hyperuricemia; Lower Extremity; Mendelian Randomization Analy | 2023 |
Serum uric acid levels and the risk of recurrent venous thromboembolism.
Topics: Anticoagulants; Humans; Prospective Studies; Recurrence; Risk Factors; Uric Acid; Venous Thromboembo | 2021 |
Venous thromboembolism in patients with gout and the impact of hospital admission, disease duration and urate-lowering therapy.
Topics: Aged; Case-Control Studies; Female; Gout; Gout Suppressants; Hospitalization; Humans; Length of Stay | 2019 |
Serum uric acid, gout, and venous thromboembolism: The atherosclerosis risk in communities study.
Topics: Atherosclerosis; Biomarkers; Female; Gout; Humans; Middle Aged; Prospective Studies; Risk Factors; U | 2016 |